Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CEE 03320

Drug Profile

CEE 03320

Alternative Names: CEE 03-320; CEE 320; NNC 220215

Latest Information Update: 11 Aug 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer CeNeS Pharmaceuticals
  • Class Antipsychotics; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Drug abuse; Schizophrenia; Sleep disorders

Most Recent Events

  • 11 Aug 2005 Discontinued - Preclinical for Drug abuse in United Kingdom (unspecified route)
  • 11 Aug 2005 Discontinued - Preclinical for Schizophrenia in Denmark (unspecified route)
  • 11 Aug 2005 Discontinued - Preclinical for Sleep disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top